Adding Sarclisa (isatuximab) to carfilzomib.lenalidomide and dexamethasone (KRd) caused a statistically significant improvement in the rate of minimal residual 11 December 2023
Britain’s largest drugmaker, AstraZeneca, has announced positive long-term results from the Phase III ALPHA trial at the annual meeting of the American Society 11 December 2023
US pharma major Bristol Myers Squibb has presented updated results from the primary analysis of the Phase III COMMANDS trial at the 2023 American Society of Hem 10 December 2023
With the end of the year approaching, it is again time for The American Society of Hematology (ASH) Annual Meeting, the last major pharmaceutical conference in 9 December 2023
Hematology company Syros Pharmaceuticals has announced “strong and encouraging” initial data from its ongoing mid-stage trial, SELECT-AML-1. 7 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.